News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
37–43
Matches
43
Sources here
5
Companies here
1
Search results Stored financial headlines

Active search

43 matching headlines

Ticker or company: MXCTMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Investing.com Nigeria Market update Main company 🇺🇸 United States

Genentech licenses MaxCyte cell engineering technology By Investing.com

MaxCyte Inc. has announced a technology license partnership with Genentech, a member of the Roche Group, to support cell therapy program development. This agreement grants Genentech access to MaxCyte’s ExPERT GTx platform and other platform technologies, enabling support for ex vivo applications in cell …

MXCT main company
Sharemaestro market context Trend signal active 52 weeks -7.0% · Next-week setup negative 39.3% MXCT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Pluang Deals and strategy Main company 🇺🇸 United States

MaxCyte licenses cell therapy tech to Genentech for research and manufacturing support

MaxCyte has announced a technology license partnership with Genentech, granting Genentech access to its ExPERT GTx® platform and other technologies. This multi-program license will support Genentech's cell therapy development across research, clinical development, and manufacturing. The collaboration aims to advance next-generation cell therapies by …

MXCT main company
Sharemaestro market context Trend signal active 52 weeks -7.0% · Next-week setup negative 39.3% MXCT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
The Manila Times Deals and strategy Main company 🇺🇸 United States

MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development

MaxCyte, Inc. announced a technology license partnership with Genentech, a member of the Roche Group, to support the development of cell therapy programs. This agreement grants Genentech access to MaxCyte’s ExPERT GTx® platform and other platform technologies for research, clinical development, and manufacturing. The …

MXCT main company
Sharemaestro market context Trend signal active 52 weeks -7.0% · Next-week setup negative 39.3% MXCT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Quartr Earnings Main company 🇺🇸 United States

MaxCyte (MXCT) Proxy filing Summary

This article summarizes MaxCyte's proxy filing from April 29, 2026, detailing voting matters and corporate governance. Key points include the election of three Class II directors and the ratification of CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending …

MXCT main company
Sharemaestro market context Trend signal active 52 weeks -7.0% · Next-week setup negative 39.3% MXCT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Quartr Earnings Main company 🇺🇸 United States

MaxCyte (MXCT) The 44th Annual William Blair Growth Stock Conference Summary

This summary details MaxCyte's (MXCT) presentation at the 44th Annual William Blair Growth Stock Conference. Key points include the evolving landscape of cell and gene therapy, MaxCyte's proprietary electroporation technology and platform capabilities, and its business model and financial performance, which features a razor-razorblade …

MXCT main company
Sharemaestro market context Trend signal active 52 weeks -7.0% · Next-week setup negative 39.3% MXCT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
The Manila Times Earnings Main company 🇺🇸 United States

MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026

MaxCyte, Inc. announced that it will release its second quarter 2026 financial results after the U.S. market closes on Wednesday, August 12, 2026. The company will host a conference call at 4:30 p.m. Eastern Time to discuss these results. Investors are encouraged to register …

MXCT main company
Sharemaestro market context Trend signal active 52 weeks -7.0% · Next-week setup negative 39.3% MXCT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

MaxCyte will discuss second-quarter results on Aug. 12

MaxCyte (NASDAQ: MXCT) announced it will release its second quarter 2026 financial results after the U.S. market closes on Wednesday, August 12, 2026. Following the release, company management will host an earnings conference call at 4:30 p.m. Eastern Time, which investors can access via …

MXCT main company
Sharemaestro market context Trend signal active 52 weeks -7.0% · Next-week setup negative 39.3% MXCT stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context